Date Action Amount Person Type
Feb 29, 2024 Sell 8 661 Dahan Michel Common Stock
Feb 29, 2024 Sell 5 974 Hadas Nicole R. Common Stock
Feb 29, 2024 Sell 46 570 Butler John P. Common Stock
Feb 29, 2024 Sell 7 169 Burke Steven Keith Common Stock
Feb 27, 2024 Sell 7 411 Hadas Nicole R. Common Stock
Feb 27, 2024 Sell 10 744 Dahan Michel Common Stock
Feb 27, 2024 Sell 8 367 Burke Steven Keith Common Stock
Feb 27, 2024 Sell 37 733 Butler John P. Common Stock
Feb 01, 2024 Sell 46 489 Butler John P. Common Stock
Feb 01, 2024 Sell 24 311 Burke Steven Keith Common Stock
Jan 31, 2024 Buy 454 950 Grund Nicholas Stock Option (Right to buy)
Jan 31, 2024 Buy 303 300 Grund Nicholas Common Stock
Jan 31, 2024 Buy 336 000 Malabre Richard C Stock Option (Right to buy)
Jan 31, 2024 Buy 223 950 Malabre Richard C Common Stock
Jan 31, 2024 Buy 149 300 Dahan Michel Common Stock
Jan 31, 2024 Buy 224 000 Dahan Michel Stock Option (Right to buy)
Jan 31, 2024 Buy 149 300 Snow Ellen Common Stock
Jan 31, 2024 Buy 224 000 Snow Ellen Stock Option (Right to buy)
Jan 31, 2024 Buy 149 300 Hadas Nicole R. Common Stock
Jan 31, 2024 Buy 224 000 Hadas Nicole R. Stock Option (Right to buy)
Jan 31, 2024 Buy 603 500 Butler John P. Common Stock
Jan 31, 2024 Buy 905 200 Butler John P. Stock Option (Right to buy)
Jan 31, 2024 Buy 202 200 Burke Steven Keith Common Stock
Jan 31, 2024 Buy 303 300 Burke Steven Keith Stock Option (Right to buy)
Jan 08, 2024 Buy 0 Grund Nicholas
Jan 08, 2024 Buy 0 Malabre Richard C
Jul 31, 2023 Buy 560 000 Snow Ellen Stock Option (Right to buy)
Jul 31, 2023 Buy 370 000 Snow Ellen Common Stock
Jul 10, 2023 Buy 0 Snow Ellen
Jun 06, 2023 Buy 45 000 Zumwalt Leanne M Stock Option (Right to buy)
Jun 06, 2023 Buy 30 000 Zumwalt Leanne M Common Stock
Jun 06, 2023 Buy 30 000 Rogers Michael W Common Stock
Jun 06, 2023 Buy 45 000 Rogers Michael W Stock Option (Right to buy)
Jun 06, 2023 Buy 45 000 Frieson Ron Stock Option (Right to buy)
Jun 06, 2023 Buy 30 000 Frieson Ron Common Stock
Jun 06, 2023 Buy 30 000 Wolf Myles Common Stock
Jun 06, 2023 Buy 45 000 Wolf Myles Stock Option (Right to buy)
Jun 06, 2023 Buy 30 000 Adams Adrian Common Stock
Jun 06, 2023 Buy 45 000 Adams Adrian Stock Option (Right to buy)
Jun 06, 2023 Buy 30 000 Smith Cynthia Common Stock
Jun 06, 2023 Buy 45 000 Smith Cynthia Stock Option (Right to buy)
Jun 06, 2023 Buy 30 000 Gilman Steven C Common Stock
Jun 06, 2023 Buy 45 000 Gilman Steven C Stock Option (Right to buy)
May 25, 2023 Sell 63 186 Hadas Nicole R. Common Stock
May 25, 2023 Sell 95 478 Dahan Michel Common Stock
May 24, 2023 Buy 200 000 Hadas Nicole R. Common Stock
May 24, 2023 Buy 200 000 Hadas Nicole R. Employee Stock Option (Right to buy)
May 24, 2023 Buy 200 000 Dahan Michel Common Stock
May 24, 2023 Buy 200 000 Dahan Michel Employee Stock Option (Right to buy)
May 16, 2023 Sell 63 567 Burke Steven Keith Common Stock
May 16, 2023 Sell 63 567 Spellman David A Common Stock
May 12, 2023 Buy 100 000 Hadas Nicole R. Common Stock
May 12, 2023 Buy 200 000 Dahan Michel Common Stock
Mar 01, 2023 Sell 38 259 Butler John P. Common Stock
Mar 01, 2023 Sell 47 239 Butler John P. Common Stock
Mar 01, 2023 Sell 6 370 Butler John P. Common Stock
Mar 01, 2023 Sell 5 333 Hadas Nicole R. Common Stock
Mar 01, 2023 Sell 6 613 Hadas Nicole R. Common Stock
Mar 01, 2023 Sell 1 088 Hadas Nicole R. Common Stock
Mar 01, 2023 Sell 6 613 Burke Steven Keith Common Stock
Mar 01, 2023 Sell 6 400 Burke Steven Keith Common Stock
Mar 01, 2023 Sell 1 110 Burke Steven Keith Common Stock
Mar 01, 2023 Sell 8 058 Dahan Michel Common Stock
Mar 01, 2023 Sell 10 476 Dahan Michel Common Stock
Mar 01, 2023 Sell 1 878 Dahan Michel Common Stock
Mar 01, 2023 Sell 6 400 Spellman David A Common Stock
Mar 01, 2023 Sell 810 Spellman David A Common Stock
Feb 27, 2023 Sell 38 632 Butler John P. Common Stock
Feb 27, 2023 Sell 7 539 Burke Steven Keith Common Stock
Feb 27, 2023 Sell 10 090 Dahan Michel Common Stock
Feb 27, 2023 Sell 7 539 Spellman David A Common Stock
Feb 27, 2023 Sell 6 677 Hadas Nicole R. Common Stock
Jan 31, 2023 Buy 293 125 Butler John P. Common Stock
Jan 31, 2023 Buy 875 000 Butler John P. Stock Option (Right to buy)
Jan 31, 2023 Buy 635 313 Butler John P. Stock Appreciation Right
Jan 31, 2023 Buy 196 200 Spellman David A Common Stock
Jan 31, 2023 Buy 294 300 Spellman David A Stock Option (Right to buy)
Jan 31, 2023 Buy 196 200 Burke Steven Keith Common Stock
Jan 31, 2023 Buy 294 300 Burke Steven Keith Stock Option (Right to buy)
Aug 31, 2022 Sell 1 147 Burke Steven Keith Common Stock
Jun 08, 2022 Buy 200 000 Spellman David A Common Stock
Jun 08, 2022 Buy 200 000 Spellman David A Stock Option (Right to buy)
Jun 08, 2022 Buy 20 100 Zumwalt Leanne M Stock Option (Right to buy)
Jun 08, 2022 Buy 13 700 Wolf Myles Common Stock
Jun 08, 2022 Buy 20 100 Wolf Myles Stock Option (Right to buy)
Jun 08, 2022 Buy 20 100 Wolf Myles Stock Option (Right to buy)
Jun 08, 2022 Buy 13 700 Smith Cynthia Common Stock
Jun 08, 2022 Buy 20 100 Smith Cynthia Stock Option (Right to buy)
Jun 08, 2022 Buy 20 100 Rogers Michael W Stock Option (Right to buy)
Jun 08, 2022 Buy 20 100 Gilman Steven C Stock Option (Right to buy)
Jun 08, 2022 Buy 13 700 Frieson Ron Common Stock
Jun 08, 2022 Buy 13 700 Adams Adrian Common Stock
Jun 08, 2022 Buy 20 100 Adams Adrian Stock Option (Right to buy)
Jun 08, 2022 Buy 20 100 Adams Adrian Stock Option (Right to buy)
Jun 03, 2022 Sell 4 567 Gilman Steven C Common Stock
May 12, 2022 Buy 200 000 Burke Steven Keith Stock Option (Right to buy)
May 12, 2022 Buy 150 000 Cotreau Violetta Common Stock
Mar 01, 2022 Sell 24 811 Butler John P. Common Stock
Mar 01, 2022 Sell 25 031 Butler John P. Common Stock
Feb 28, 2022 Buy 293 125 Butler John P. Common Stock
INSIDER POWER
84.191
Last 100 transactions
Buy: 11 050 463 | Sell: 761 907 (Shares)

Based on the 100 latest insides trades, we have calculated the insider power to be positive at a ratio of 84.191.

In total, the insiders bought 11 050 463 and sold 761 907 AKBA shares in the last 100 trades.

Click to get the best stock tips daily for free!

About Akebia Therapeutics

Akebia Therapeutics Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citra... AKBA Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT